Chinese developer of extended-release and low-dose generic drugs, with many products cleared for sale in the US.
Chinese developer of extended-release and low-dose generic drugs, with many products cleared for sale in the US.
Earns from generic drugs it designs itself, chiefly extended-release forms that release the drug slowly and are harder to copy than ordinary tablets. Each US FDA approval lets it start selling a new product, so the pipeline of approvals drives growth. It listed on Shenzhen's ChiNext board in October 2026.
In one line: A small, China-based Amneal focused on harder-to-make generics.
Moat: narrow (process know-how, regulatory licence). Harder-to-make formulations and a record of US FDA approvals limit the number of rivals.
Headquarters: Nantong, China · Employees: 697
Size Novast Laboratories (301569.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.92B, the 616th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.00 on 18 Nov 2026.
Growth Revenue grew 3.1% over the last twelve months (peer median +7.9%); the operating margin is 27.4% (peer median 15.7%).
Valuation It trades at 27.6× enterprise value to sales against a peer median of 3.3× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +54 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.2 points above its cost of capital (13.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | CN¥893M | CN¥866M | CN¥700M |
| Revenue growth | — | +3% | +24% | — |
| Gross profit | n/a | CN¥490M | CN¥465M | CN¥343M |
| EBITDA | n/a | CN¥281M | CN¥273M | CN¥121M |
| Net income | n/a | CN¥228M | CN¥260M | CN¥116M |
| Free cash flow | n/a | CN¥250M | CN¥165M | CN¥78.8M |
| Capital expenditure | n/a | CN¥75.3M | CN¥106M | CN¥127M |
| Total debt | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Novast Laboratories 301569.SZ | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% |
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 3.6× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301569.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.6% | +4.6% | lowest of 21 |
| Distance from 52-week high | -62.0% | -26.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +3.1% | +7.9% | 8th lowest of 18 |
| Operating margin | 27.4% | 15.7% | 4th highest of 17 |
| EV / Sales | 27.6× | 3.3× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 57.4% | 3.0% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +3.1% | +6.7% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +54.3 pp | -9.1 pp | most demanding of 15 |
| ROIC minus cost of capital | +7.2 pp | +4.3 pp | 7th highest of 18 |
| EV / EBITDA | 88.3× | 15.2× | most expensive of 10 |
| Net debt / EBITDA | -5.0× | 0.2× | least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% | +3.1% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% | +7.5% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 5.5× | 0.9% | +45.1% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 2.3× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 5.1× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 2.3× | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 2.0× | -5.0% | +3.2% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 5.8× | 12.4% | +9.7% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 16.6× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 3.2× | -9.9% | +0.3% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |